Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to $203997.0.

  • Bioadaptives' Accumulated Expenses rose 2578.66% to $203997.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $203997.0, marking a year-over-year increase of 2578.66%. This contributed to the annual value of $171507.0 for FY2024, which is 2432.1% up from last year.
  • As of Q3 2025, Bioadaptives' Accumulated Expenses stood at $203997.0, which was up 2578.66% from $190167.0 recorded in Q2 2025.
  • In the past 5 years, Bioadaptives' Accumulated Expenses registered a high of $203997.0 during Q3 2025, and its lowest value of $1019.0 during Q1 2023.
  • Its 5-year average for Accumulated Expenses is $96000.1, with a median of $113606.5 in 2022.
  • In the last 5 years, Bioadaptives' Accumulated Expenses tumbled by 9860.58% in 2023 and then skyrocketed by 1422316.0% in 2024.
  • Over the past 5 years, Bioadaptives' Accumulated Expenses (Quarter) stood at $6200.0 in 2021, then skyrocketed by 1527.73% to $100919.0 in 2022, then soared by 36.7% to $137955.0 in 2023, then rose by 24.32% to $171507.0 in 2024, then increased by 18.94% to $203997.0 in 2025.
  • Its Accumulated Expenses stands at $203997.0 for Q3 2025, versus $190167.0 for Q2 2025 and $180837.0 for Q1 2025.